Summary Bolus 5-fluorouracil (5-FU) is a phase-specific drug with a short plasma half-life that is used in combination with bolus cyclophosphamide and methotrexate in the treatment of breast cancer. The efficacy of 5-FU can be improved by continuous intravenous infusion using portable infusion pumps (infusional 5-FU). Infusional 5-FU, 200 mg m-2 day-1, in combination with standard doses of bolus cyclophosphamide and methotrexate, was evaluated in a phase I/Il dose-finding study. The cyclophosphamide and methotrexate were administered in 28-day cycles as follows: cohort 1, cyclophosphamide 600 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1; cohort 2, cyclophosphamide 400 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1; cohort 3, cyclophosphamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1; cohort 4, cyclophosphamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, days 1 and 8. Median overall survival was 10 months (range 3-21 months). Objective tumour responses were seen in 9 of 25 patients (36%, 95% Cl 18-58%), including 3 of 13 patients (23%) previously treated for metastatic disease. Cohorts 1 and 4 proved to be too toxic, with five of six patients in cohort 1 and three of four in cohort 4 developing grade III/IV neutropenia. The dose intensity of cyclophosphamide achieved was as follows: cohort 1, 82%; cohort 2, 86%; cohort 3, 97%; cohort 4, 90%. Infusional 5-FU can be administered safely and is effective in combination with cyclophosphamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1, in the treatment of metastatic breast cancer.
5-Fluorouracil (5FU) was one of the earliest cytotoxic agents developed for the treatment of cancer and is a principal drug used in the management of breast and colorectal carcinomas. Owing to a highly variable bioavailability following oral administration, the intravenous route is considered to be the most efficacious (Christophidis et al, 1978) . Following intravenous bolus injection, 5-FU has a rapid tissue distribution and very short plasma half-life, the drug being undetectable 2 h after administration (Heggie et al, 1987) . Between 60% and 90% of injected 5-FU or its metabolites can be recovered from urine within 24 h of administration (McDermott et al, 1982) . Myelosuppression and mucositis are the main dose-limiting sideeffects of bolus administration. Larger cumulative doses are well tolerated following continuous infusion as a consequence of the altered plasma concentration profile (Spicer et al, 1988) . This schedule of administration results in less severe myelosuppression but an increased incidence of palmar-plantar syndrome (Lokich et al, 1981 (Lokich et al, , 1983 Huan et al, 1989; Jabboury et al, 1989; Hansen, 1991) . With the development of small portable infusion pumps it has been possible to evaluate the activity and toxicity of continuous, ambulatory, intravenous administration of 5-FU alone or in combination with other drugs. Studies of single-agent infusional 5-FU at doses of up to 300 mg m-2 day-' in advanced breast cancer show that it is well tolerated with response rates of between 16% and 53% (Hansen et al, 1987; Huan et al, 1989; Jabboury et al, 1989; Ng et al, 1994) , including a response rate of 30% in patients with disease refractory to conventional chemotherapy (Hansen, 1991) . High response rates have been reported when infusional 5-FU is combined with bolus epirubicin and cisplatin (Smith et al, , 1995 Jones et al, 1994) .
The combination of bolus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is the most frequently used chemotherapy regimen in the management of breast cancer (Bonnadona and Valagusa, 1985; Tannock et al, 1988; Engelsman et al, 1991; Brandi et al, 1994) . Continuous infusional 5-FU, rather than bolus injections, may further improve the efficacy of this combination. The dose intensity of cyclophosphamide is considered to be an important factor in the activity of CMF (Henderson et al, 1988) . The 'classical' CMF regimen (28-day cycle) delivers a higher dose intensity than the 21-day intravenous bolus schedule and a better response rate has been reported (Engelsman et al, 1991) .
One of the potential problems with using infusional 5-FU in combination with cyclophosphamide and methotrexate is exacerbation of myelotoxicity. The primary aim of the present study was to evaluate the efficacy and tolerability of a modified 'classical' CMF regimen replacing bolus 5-FU with continuous infusional 5-FU, given at 200 mg m-2 day-l, to lay the foundation for future randomized studies comparing infusional CMF with standard bolus treatments in the management of metastatic breast cancer. [aspartate aminotransferase (AST), y-glutamyl transferase (yGT) and alkaline phosphatase (ALP)] . three times the upper limit of normal (unless caused by hepatic metastases), pregnancy or concomitant serious clinical illness. Previous chemotherapy, including adjuvant CMF chemotherapy or endocrine treatment, was not an exclusion criterion.
As the agents employed were being used within their licensed indication, the study was not submitted to the Research Ethics Committee. However, all patients received an information sheet detailing the nature of the treatment, the procedures involved and the potential side-effects of therapy and were only started on treatment after giving their informed consent.
Treatment
The initial treatment schedule chosen was a modification of the Iclassical' CMF regimen, with cyclophosphamide 600 mg m-2 being administered i.v. on days 1 and 8 of a 28-day cycle rather than cyclophosphamide 100 mg m-2 orally days 1-14. The infusional 5-FU dose was based on that used in previous studies in breast cancer either alone or in combination with epirubicin and cisplatin (Huan et al, 1989; Jones et al, 1994; Ng et al, 1994) . In experimental models methotrexate has been shown to potentiate the antitumour activity of 5-FU. As a result of this potentiation, the side-effects of both agents may be increased. For this reason day 8 methotrexate was omitted in the initial schedule (Sotos et al, 1994) . The enrolment schedule to the modified 'classical' infusional CMF regimen was based on standard criteria for a phase I study. We planned to recruit between three and six patients to the initial cohort based on the toxicities seen. If the initial schedule was well tolerated we planned to increase the dose intensity of methotrexate, administering it on day 8 also. Cyclophosphamide is recognized to be the main factor in CMF-induced toxicity (DeBrujn et al, 1991; Shapiro et al, 1993) . Therefore, in the case of significant toxicities we intended to reduce the dose of cyclophosphamide by 33% such that the dose intensity of cyclophosphamide would be equivalent to that of standard 21-day bolus CME Subsequent dose adjustments would be based on the experience gained with each treated cohort.
Before starting chemotherapy, a Hickman catheter was inserted via the subclavian route and warfarin 1 mg p.o. daily commenced as prophylaxis against thrombotic events (Bern et al, 1990; Brown-Smith et al, 1990; Eastridge and Lefor, 1995) . The treatment was managed on an outpatient basis with infusional 5-FU at a dose of 200 mg m-2 day-', administered as a continuous ambulatory infusion using a portable pump (Walkmed 350, Medfusion, Duluth, GA, USA). The infusion bag contained 5-FU in a total volume of 120 ml, at a concentration of 25 mg ml-' (3 g total). Palmar-plantar erythrodysthesia, a potential complication of infusional 5-fluorouracil therapy, was treated with pyridoxine 50 mg t.i.d., p.o. (Fabian et al, 1990) . The infusion was continued until disease progression or 24 weeks of treatment had been completed.
Three dose levels of cyclophosphamide were evaluated: 600 mg m-2, cohort 1; 400 mg m-2, cohort 2; and 480 mg m-2, cohorts 3 and 4. Methotrexate 40 mg m-2was administered on day 1 in cohorts 1, 2 and 3, and on days 1 and 8 in cohort 4 ( Patients were assessed weekly with a full blood count and toxicity scored using standard WHO criteria. Renal, liver and bone biochemical profiles were performed at the end of each treatment cycle. The doses of cyclophosphamide and methotrexate were reduced by 25% in patients experiencing grade III or IV haematological or non-haematological toxicity apart from alopecia or nausea and vomiting, which could be controlled with standard antiemetics. The 5-FU infusion was interrupted for 1 week whenever the neutrophil count fell to < 1.5 x 109 1-'. The subsequent cycle was delayed only if the neutrophil count had not recovered by the end of the cycle. Response evaluation according to WHO criteria was performed after the second, fourth and sixth cycles of treatment. Treatment was discontinued in patients with progressive disease.
RESULTS
Patients' characteristics are summarized in Table 2 . Twenty-five women, median age 51 years (range 33-69 years) with stage IV breast cancer, were recruited to the study. Six patients were recruited to cohort 1. Because severe haematological toxicities were seen in the initial cohort, and because of a number of sideeffects seen in cohort 2 (see below), we were cautious about increasing the dose of cyclophosphamide to that used in cohorts 3 and 4. As a result, cohort 2 was expanded to include 11 patients. Four patients were recruited to each of cohorts 3 and 4.
Haematological toxicity A total of 107 cycles of infusional CMF chemotherapy were administered, all of which were evaluated for toxicity (Table 3) . The principal toxicity seen in cohort 1 was grade III/IV leucopenia, which occurred in all six patients, five having grade III/IV neutropenia. In the subsequent patient cohort, the cyclophosphamide was reduced by 33% to 400 mg m-2, days 1 and 8. Of 11 patients recruited to cohort 2, grade III/IV neutropenia developed in four, one of whom developed grade III/IV thrombocytopenia. In cohorts 3 and 4 the cyclophosphamide dose was
effects were seen. In cohort 4 methotrexate was administered on days 1 and 8. Grade III/IV neutropenia developed in two patients and was associated with pyrexia in one and grade III fatigue in the other. The patient with the neutropenic pyrexia also developed grade III anaemia, grade IV thrombocytopenia, grade IV mucositis and grade III nausea and vomiting. As a result of these excessive toxicities, the regimen was discontinued after a total of six cycles of treatment had been administered to four patients. In subsequent cycles the day-8 methotrexate was omitted and the four patients were treated as in cohort 3. Although 3 patients developed grade III/IV neutropenia on one occasion each, no sepsis or other significant side-effects were seen.
Non-haematological toxicities
Fatigue was experienced by 13 of the 25 (52%) patients recruited to the study, with grade III/IV fatigue being experienced by one patient in each of cohorts 1, 2 and 4. In two cases, the grade III/IV fatigue was associated with grade IV neutropenia. Treatment was stopped in one patient in cohort 2 with persistent grade II fatigue. Nausea was well controlled by metoclopramide and dexamethasone. Grade II nausea was seen in two patients, one each from cohorts 1 and 2. (Tables 2 and 5 ). Of 13 patients previously treated with cytotoxic agents for metastatic disease, three patients (23%), including two also previously treated with adjuvantlneoadjuvant cytotoxic chemotherapy, responded to treatment (Tables I and 4 ).
The median survival for all 25 patients was 10 months (range 3-28 months) with one patient in cohort 3 still alive after 28 months at last follow-up.
DISCUSSION
The combination of cyclophosphamide, methotrexate and 5-FU is a commonly used regimen for the adjuvant treatment of breast cancer and for the management of advanced disease when response rates of 29-60% are reported (Tannock et al, 1988; Engelsman et al, 1991; Falkson et al, 1991; Smith and Powles, 1993; Brandi et al, 1994; Hayes et al, 1995) . Other cytotoxic regimens used in the treatment of metastatic or relapsed breast cancer include mitomycin-C-mitoxantrone-methotrexate (MMM), single-agent taxane therapy and anthracycline-based regimens including cyclophosphamide, doxorubicin and 5-fluorouracil (CAF), and doxorubicin or epirubicin and paclitaxel (Smith and Powles, 1993; Hayes et al, 1995; Capri et al, 1996; Luck et al, 1996) . MMM has equivalent response rates to CMF chemotherapy Smith and Powles, 1993) . Response rates to CAF are consistently higher (55-82%) than those of CMF and there may be a survival advantage of CAF compared with CMF (Falkson et al, 1991; Pfeiffer et al, 1992 , Hayes et al, 1995 . On the other hand, toxicity associated with CAF chemotherapy, in particular haematological toxicity, emesis and alopecia, is substantially higher (Greene et al, 1994; Hayes et al, 1995) . On the basis of available evidence of efficacy, CMF continues to be widely used as first-line therapy for patients with newly diagnosed metastatic breast cancer (Hayes et al, 1995) .
The rationale for using infusional 5-FU administration is based on the S-phase-specific nature of the drug and its short plasma half-life. Bolus administration is followed by rapid tissue distribution and short elimination half-life (Heggie et al, 1987) . As a result, only a small proportion of tumour cells are exposed to appropriate concentrations of 5-FU at the sensitive phase of the cell cycle. Administration of infusional 5-FU would theoretically increase the exposure of sensitive tumour cells to the drug. Initial studies of protracted intravenous infusion of 5-FU were performed in the treatment of colorectal cancer. These demonstrated that 5-FU 300 mg m-2 could be administered by continuous infusion, without interruption, for up to 60 days or up to 36 g cumulative dose (Lockich et al, 1981) . Subsequent work showed a higher response rate with infusional than bolus injection (Lokich et al, 1983) . Single-agent infusional 5-FU at doses of 200-300 mg m-2 daily has been reported to have activity in metastatic breast cancer (Jabboury et al, 1989; Ng et al, 1994) , with one study reporting a response rate of 53% in heavily pretreated patients (Huan et al, 1989) . In a review of six phase II infusional 5-FU studies in metastatic breast cancer a mean response rate of 29% was reported (Hansen, 1991) . Non-randomized studies on large operable breast tumours treated with a combination of infusional 5-FU and bolus epirubicin and cisplatin (ECF) show response rates of up to 98% (Smith et al, , 1995 . Furthermore, an overall response rate of 84% has been reported for ECF in 43 patients with metastatic (29 patients) and locally advanced (14 patients) breast cancer including a complete response rate of 24% in the metastatic patients . Both the unique combination of agents together with the higher overall dose of 5-FU administered in each cycle compared with that normally given in bolus regimens may have contributed to this encouraging anti-tumour activity.
Infusional CMF in metastatic breast cancer 1955
The present study set out to establish the best-tolerated dose of cyclophosphamide and methotrexate, given in a modified 'classical' schedule, that could be used concomitantly with continuous infusional 5-FU at a dose of 200 mg m-2 in the treatment of metastatic or relapsed breast cancer. This study demonstrates that cyclophosphamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1, is well tolerated when combined with infusional 5-FU in the treatment of metastatic breast cancer.
Fatigue/lethargy was the most frequently reported side-effect, being seen in just over half the patients in our study. Fatigue was severe (grade III) in three patients. One patient with persistent grade II fatigue elected to discontinue her treatment for this reason. Fatigue/lethargy is a well-recognized complication of CMF and our findings are in keeping with those reported for the classical CMF chemotherapy regimen . The palmar-plantar syndrome, a complication of 5-FU, is seen more frequently with infusional treatment in which up to 26% of patients develop grade III toxicity Smith et al, 1995) . We observed grade II palmar-plantar syndrome in only one patient. Oral pyridoxine has been reported as an effective therapy when this condition occurs as a side-effect of 5-FU treatment (Fabian et al, 1990) . In keeping with this, our patient's symptoms resolved on pyridoxine 50 mg t.i.d. p.o. Patients tolerated the ambulatory pump well as reported in previous studies (Ng et al, 1994) .
DVT occurred in 24% of our patients. In four cases this developed in relation to the Hickman line, despite the use of prophylactic warfarin from the day of its insertion. In a study of 322 indwelling venous devices, Eastridge et al (1995) observed a 10% thrombosis rate not related to coagulation profiles of the patients. Infusional 5-FU resulted in superior vena caval thrombosis in 9% of patients in the Edinburgh study (Ng et al, 1994) . It is possible that cyclophosphamide exacerbates phlebitis induced by continuous 5-FU infusion, leading to an increased risk of thrombosis.
In a study evaluating a 21-day schedule of infusional CMF in 28 patients, cyclophosphamide 750 mg m-2 and methotrexate 50 mg m-2 were given as i.v. bolus injections on day I only. The infusional 5-FU was administered as in the present study. Despite the fact that 23 patients had received previous chemotherapy, the overall response rate was 50%. This included two patients with a complete response who had had anthracycline-containing regimens for metastatic liver and extensive locally recurrent disease. The 21-day regimen was well tolerated, grade III neutropenia being observed in 12 patients, grade III mucositis in nine and grade II palmar-plantar syndrome in four (Mackay et al, 1996) . These results are consistent with the findings of our study, in which 36% response rate (CI = 18-58%) was seen. Although precise details of the DI of cyclophosphamide achieved is not given in their study, the planned DI, 35.7 mg m-2, is similar to that of the planned regimen received by patients in cohorts 3 and 4 of our study, 34.3 mg m-2.
This study demonstrates that cyclophosphamide 480 mg m-2, day 1 and 8, and methotrexate 40 mg m-2, day 1, appear well tolerated in combination with continuous infusional 5-FU, 200 mg m-2 day-'. Taken in conjunction with the results reported by Mackay et al (1996) , this study supports the contention that infusional CMF chemotherapy may have a role to play in the management of metastatic breast cancer. These findings have laid the groundwork for a randomized trial comparing infusional CMF with conventional CMF and other combination regimens in the treatment of locally advanced and metastatic breast cancer.
